Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Accounts Payables (2018 - 2025)

Addex Therapeutics' Accounts Payables history spans 8 years, with the latest figure at $754331.5 for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 16.86% to $754331.5 in Q4 2025 year-over-year; TTM through Dec 2025 was $754331.5, a 16.86% decrease, with the full-year FY2025 number at $727176.1, down 19.85% from a year prior.
  • Accounts Payables came in at $754331.5 for Q4 2025, down from $1.5 million in the prior quarter.
  • The five-year high for Accounts Payables was $4.8 million in Q1 2021, with the low at $754331.5 in Q4 2025.
  • Historically, Accounts Payables has averaged $2.6 million across 5 years, with a median of $2.7 million in 2023.
  • Biggest five-year swings in Accounts Payables: skyrocketed 61.36% in 2021 and later plummeted 72.23% in 2025.
  • Year by year, Accounts Payables stood at $1.9 million in 2021, then surged by 60.44% to $3.1 million in 2022, then decreased by 13.57% to $2.7 million in 2023, then plummeted by 66.25% to $907266.7 in 2024, then dropped by 16.86% to $754331.5 in 2025.
  • Business Quant data shows Accounts Payables for ADXN at $754331.5 in Q4 2025, $1.5 million in Q3 2025, and $1.4 million in Q2 2025.